Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

NCT06430905 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped business decision

Conditions

Human Immunodeficiency Virus (HIV) Infection

Interventions

BIOLOGICAL: HB-502 and HB-501 alternating 2-vector therapy Dose Level 1
BIOLOGICAL: HB-502 and HB-501 alternating 2-vector therapy Dose Level 2
OTHER: Placebo

Sponsor

Hookipa Biotech GmbH